Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral fosfomycin versus ciprofloxacin for febrile urinary tract infection in men
NL-OMON25027Not yet recruiting
- Sponsor
- HagaZiekenhuis
- Start
- Jun 2018
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Open-label trial of fosfomycin and ciprofloxacin in urinary tract infection (UTI) and uropathogenic Escherichia coli infection (2 arms), sponsored by HagaZiekenhuis. Primary endpoint: Clinical cure rate at test of cure. Planned start Jun 2018; status: not yet recruiting.
02
Drugs
fosfomycinciprofloxacin
03
Conditions
urinary tract infection (UTI)uropathogenic Escherichia coli infection
Beyond the preview
Go deeper on NL-OMON25027.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON25027.